JENNIFER WARGO to Phenotype
This is a "connection" page, showing publications JENNIFER WARGO has written about Phenotype.
Connection Strength
0.179
-
Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clin Cancer Res. 2021 10 01; 27(19):5365-5375.
Score: 0.022
-
Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. Cancer Immunol Res. 2020 11; 8(11):1365-1380.
Score: 0.020
-
Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020 01; 577(7791):561-565.
Score: 0.019
-
B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020 01; 577(7791):549-555.
Score: 0.019
-
B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020 01; 577(7791):556-560.
Score: 0.019
-
A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITFhigh /AXLlow melanoma. Pigment Cell Melanoma Res. 2019 03; 32(2):280-291.
Score: 0.018
-
Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients. Cancer. 2017 04 15; 123(8):1372-1381.
Score: 0.015
-
sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. 2016 Apr 14; 532(7598):250-4.
Score: 0.015
-
Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. J Immunol. 2014 Nov 01; 193(9):4722-31.
Score: 0.013
-
Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov. 2013 Dec; 3(12):1378-93.
Score: 0.012
-
Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother. 2004 Sep-Oct; 27(5):354-67.
Score: 0.007